SCHEMBL6798748

SCHEMBL6798748

O=C(O)C[C@H](NC(=O)CNS(=O)(=O)c1ccc2ccccc2c1)C(=O)C1CCCCN1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 2/20 0.45
CTSS P25774 1/20 0.45
PLAT P00750 2/20 0.43
ALDH1A1 P00352 2/20 0.43
F2 P00734 3/20 0.42
PLAU P00749 1/20 0.42
PKM P14618 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
LMNA P02545 1/20 0.40
TPSAB1 Q15661 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786061 0.88 F2 (0.47) PLATF2F10NPY5R
SCHEMBL8696361 0.82 CTSS (0.50) KAT6ACTSSALDH1A1F2PKM
SCHEMBL6786112 0.76 PLG (0.51) KAT6ACTSSPLATALDH1A1F2
SCHEMBL7919039 0.76 F10 (0.49) CTSSF2PKMHDAC3HDAC4
SCHEMBL6438335 0.70 ALDH1A1 (0.69) KAT6ACTSSALDH1A1PKMKDM4E
SCHEMBL1771503 0.68 CTSS (0.67) KAT6ACTSSALDH1A1F2PKM
SCHEMBL8684045 0.68 F2 (0.48) F2F10NPY5R
SCHEMBL7398649 0.68 ITGB3 (0.43) KAT6ACTSSPLATALDH1A1F2
Piperidine SCHEMBL7370685 0.68 F2 (0.53) KAT6APLATF2PLAUF10
SCHEMBL6787527 0.67 PLG (0.54) KAT6ACTSSPLATALDH1A1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730672-B2 PROTEASE INHIBITOR ZENECA LIMITED (GB) 2004-05-04 US disclosed
US-20020119968-A1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents ZENECA LIMITED 2002-08-29 US disclosed
US-6225309-B1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents ZENECA LIMITED (GB) 2001-05-01 US disclosed
EP-0783500-A1 AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS ZENECA LIMITED (GB) 1997-07-16 EP disclosed
WO-1996010022-A1 AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS ZENECA LIMITED (GB) 1996-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119968-A1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents SERPINC1, F2, SULT1E1 KAT6A 4118/4885CTSS 4403/4885PLAT 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.